Moderna
American biotechnology company
MRNA Nasdaq
ISIN US60770K1079 SEC CIK 1682852 LEI 549300EI6OKH5K5Q2G38
Follow Moderna
Weekly email: filings, results
Revenue, last quarter
$1.3B
+29.2% vs same quarter last year
Net income
$162M
+181% vs same quarter last year
EPS, diluted
$0.38
+174.5% vs same quarter last year
Operating cash flow
−$1.6B
−84.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.9B | −$2.8B |
| FY24 | $3.2B | −$3.6B |
| FY23 | $6.8B | −$4.7B |
| FY22 | $19.3B | $8.4B |
| FY21 | $18.5B | $12.2B |
| FY20 | $803M | −$747M |
| FY19 | $60.2M | −$514M |
| FY18 | $135.1M | −$384.7M |
| FY17 | $205.8M | −$255.9M |
| FY16 | $108.4M | −$216.2M |
| FY15 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 55.3% | −158.1% | −145.2% |
| FY24 | 54.8% | −121.9% | −110% |
| FY23 | 31.5% | −61.9% | −68.8% |
| FY22 | 71.9% | 48.9% | 43.4% |
| FY21 | 85.8% | 72% | 66.1% |
| FY20 | 99% | −95% | −93% |
| FY19 | 100% | −906.8% | −853.7% |
| FY18 | 100% | −306% | −284.8% |
| FY17 | - | −130.9% | −124.3% |
| FY16 | - | −206.4% | −199.5% |
| FY15 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$2.1B |
| FY24 | −$4.1B |
| FY23 | −$3.8B |
| FY22 | $4.6B |
| FY21 | $13.3B |
| FY20 | $2B |
| FY19 | −$491M |
| FY18 | −$436.6M |
| FY17 | −$389.9M |
| FY16 | $33.6M |
| FY15 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $2M |
| FY24 | $0 |
| FY23 | $1.2B |
| FY22 | $3.3B |
| FY21 | $857M |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
- Moderna
- Healthcare median
Show the numbers
| Year | Moderna | Healthcare median |
|---|---|---|
| FY25 | −145.2% | −30.6% |
| FY24 | −110% | −47% |
| FY23 | −68.8% | −58% |
| FY22 | 43.4% | −80.4% |
| FY21 | 66.1% | −71.9% |
| FY20 | −93% | −62.2% |
| FY19 | −853.7% | −46.3% |
| FY18 | −284.8% | −49.6% |
| FY17 | −124.3% | −45.9% |
| FY16 | −199.5% | −36% |
| FY15 | - | −38.4% |